QS-21
Based on 1 Customer Validation
QS-21 is a mixture of QS-21-Xyl (HY-101092B) and QS-21-Api (HY-101092), with a ratio of 35:65. QS-21 is an innate immune system-targeted adjuvant. QS-21 is promising for research of oncology vaccines (e.g., melanoma) and infectious disease vaccines (e.g., HIV, malaria).
For research use only. We do not sell to patients.
- Purity : 99.10%
- Formula: C92H148O46
- Molecular Weight:1990.14
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Chemical Information
-
Appearance Solid
-
Molecular Weight 1990.14
-
Formula C92H148O46
-
Color White to off-white
-
SMILES
O[C@H]1COC[C@@H](O)[C@@H]1O.O[C@H]2COC[C@]2(O)CO.O[C@H]([C@@H]([C@H]([C@@H](O3)C)O[C@H]4[C@@H]([C@H]([C@@H](CO4)O)O[R])O)O)[C@@H]3O[C@H]([C@H]([C@H]([C@H](O5)C)OC(C[C@@H](O)C[C@H](OC(C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@@H]6O[C@H]([C@@H]([C@H]6O)O)CO)=O)[C@H](CC)C)=O)O)[C@@H]5OC([C@]78[C@](CC(C)(CC8)C)([H])C9=CC[C@@]([C@@]%10([C@@]([C@@](C)([C@H](CC%10)O[C@H]%11[C@@H]([C@H]([C@@H]([C@H](O%11)C(O)=O)O)O[C@H]%12[C@@H]([C@H]([C@@H](CO%12)O)O)O)O[C@@H]%13O[C@@H]([C@@H]([C@@H]([C@H]%13O)O)O)CO)C=O)([H])CC%14)C)([H])[C@]%14(C)[C@@]9(C[C@H]7O)C)=O.[35%].[65%]
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
QS-21 Related Classifications
HY-101092A Related Classifications
Powered by Bioz